Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha Methyl Tetradecylthioacetic Acid (also known as Tetradecylthioacetic acid, or TTA) is a synthetic fatty acid analog that has been the subject of some preclinical and early clinical research regarding its effects on lipid metabolism, including triglyceride levels. The primary mechanism proposed is TTA's role as a modulator of mitochondrial beta-oxidation and as a weak peroxisome proliferator-activated receptor (PPAR) agonist, which are pathways involved in fatty acid metabolism.

Animal studies have shown that TTA supplementation can lower plasma triglycerides and improve fatty acid oxidation in various models, including rodents with diet-induced hyperlipidemia. These effects appear to result from increased mitochondrial fatty acid oxidation and decreased lipogenesis. Early human trials, though limited in size and scope, have reported some reduction in serum triglycerides in subjects with dyslipidemia after TTA administration. For example, a small randomized controlled trial in humans (N=16) found that TTA reduced fasting plasma triglycerides after 4 weeks of treatment compared to placebo.

However, the overall evidence base is limited, with few and relatively small human studies, and no large-scale randomized controlled trials to confirm efficacy and safety for this indication. Therefore, while there is a scientific rationale and some supporting data, the strength of evidence is modest, meriting a rating of 2 out of 5.

More about alpha Methyl Tetradecylthioacetic Acid
More about Triglycerides (high)

Other ingredients used for Triglycerides (high)

Other health conditions supported by alpha Methyl Tetradecylthioacetic Acid

Products containing alpha Methyl Tetradecylthioacetic Acid